Marie Cecile Van De Lavoir
About Marie Cecile Van De Lavoir
Marie Cecile Van De Lavoir serves as the Vice President of Operations at Ligand Pharmaceuticals in Emeryville, CA, a position she has held since 2017. She has a strong background in veterinary medicine and biotechnology, with significant contributions to transgenic research and embryonic stem cell development.
Work at Ligand Pharmaceuticals
Marie Cecile Van De Lavoir has served as Vice President Operations at Ligand Pharmaceuticals since 2017. In this role, she oversees various operational aspects of the company, contributing to its strategic initiatives and operational efficiency. Ligand Pharmaceuticals, based in Emeryville, CA, focuses on developing innovative therapies for various diseases. Her leadership in operations plays a crucial role in advancing the company's mission and objectives.
Education and Expertise
Marie Cecile Van De Lavoir has an extensive educational background in veterinary medicine and biotechnology. She earned her Doctor of Veterinary Medicine (DVM) degree from Utrecht University, completing her studies from 1977 to 1985. She furthered her education at Cornell University for one year before obtaining both her MSc and PhD from the University of Guelph between 1989 and 1996. This academic foundation supports her expertise in biotechnology and operations within the pharmaceutical industry.
Background
Prior to her current position, Marie Cecile Van De Lavoir held several notable roles in academia and research. She worked as a Staff Veterinarian at Utrecht University from 1986 to 1988. Later, she served as a Postdoctoral Fellow at the University of California, San Francisco from 1996 to 1999. Her diverse background in veterinary science and research has equipped her with a unique perspective in the biotechnology field.
Achievements
Marie Cecile Van De Lavoir has made significant contributions to the field of biotechnology. She played a pivotal role in developing a cell-based system for producing transgenic chickens that lay eggs containing monoclonal antibodies. Additionally, she holds several patents and patent applications related to her work. Her research has been published in prestigious journals, including Nature and Nature Biotechnology. She was also instrumental in initiating one of the first human embryonic stem cell lines at UCSF and successfully derived chicken embryonic stem cells at Origen Therapeutics.